Protagenic Therapeutics, Inc.new (PTIX) stock
Close on Oct 19, 2026Market cap $1.36MP/E –Yield –
Protagenic Therapeutics, Inc.new reported revenue of $0 for the twelve months to Dec 31, 2024. At the latest close the market valued the company at $1.36M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.36M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.79
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $0
- Net income
- -$5.53M
- EPS, diluted
- -$15.82
- Book value per share
- $0.95
- Diluted shares
- 2M
Trading
- Previous close
- $0.75
- Open
- $0.76
- Day's range
- $0.75 – $0.76
- Volume
- 1,262
- Average volume (20 days)
- 1,624
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | PTIX | S&P 500 | Difference | PTIX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -18.0% | +0.6% | −18.6 pts | ||
| 3 months | +188.5% | +3.4% | +185.1 pts | ||
| Year to date | -42.3% | +13.3% | −55.6 pts | ||
| 1 year | -76.7% | +16.6% | −93.3 pts | ||
| 3 years | -93.9% | +86.4% | −180.3 pts | -60.7% | +23.1% |
| 5 years | -99.3% | +81.9% | −181.2 pts | -62.9% | +12.7% |
Eleven years at a glance
Fiscal years 2013 to 2024, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Protagenic Therapeutics, Inc.new filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- News
- Update
- Update
About Protagenic Therapeutics, Inc.new
Pharmaceutical Preparations
Protagenic Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing therapeutics for stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of Teneurin Carboxy-terminal Associated Peptide-1 (TCAP-1), designed to counter excess stress signaling. The company targets conditions including treatment-resistant depression, substance use disorder, generalized anxiety disorder, and post-traumatic stress disorder. Through a prior reverse merger with Phytanix Bio, historical drug candidate programs also encompass preclinical assets such as potassium channel modulators, cannabinoid-based therapies, and modified stilbenoid compounds.
Company profile, executives and historyProtagenic Therapeutics, Inc.new stock: common questions
What is Protagenic Therapeutics, Inc.new's stock price?
PTIX closed at $0.75 on Oct 19, 2026, up 0.00% on the day.
What is Protagenic Therapeutics, Inc.new's market cap?
Protagenic Therapeutics, Inc.new was worth $1.36M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is PTIX's P/E ratio?
Protagenic Therapeutics, Inc.new lost money over the twelve months to Dec 31, 2024 (diluted EPS -$15.82), so it has no meaningful P/E ratio.
How much revenue does Protagenic Therapeutics, Inc.new make?
Protagenic Therapeutics, Inc.new reported revenue of $0 for the twelve months to Dec 31, 2024.
Does Protagenic Therapeutics, Inc.new pay a dividend?
No. Protagenic Therapeutics, Inc.new has not paid a cash dividend over the last twelve months.
How has PTIX stock performed over the past year?
Including dividends, PTIX returned -76.7% over the past year, against +16.6% for the S&P 500.
Who are Protagenic Therapeutics, Inc.new's competitors?
Companies most similar to Protagenic Therapeutics, Inc.new by business, industry and size include CMPS, PBM, ENVB, VTGN, XENE.
See a number that looks wrong?